| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000468521 |
| P698 | PubMed publication ID | 28478451 |
| P50 | author | Uhi Toh | Q88213258 |
| P2093 | author name string | Satoshi Hasegawa | |
| Tsuyoshi Saito | |||
| Reiki Nishimura | |||
| Toshihiro Tanaka | |||
| Maki Tanaka | |||
| Nobuyuki Arima | |||
| Kazuo Tamura | |||
| Yasuyo Ohi | |||
| Satoshi Toyoshima | |||
| Shoshu Mitsuyama | |||
| Kaname Kurashita | |||
| Michiyo Saimura | |||
| Yuichiro Kai | |||
| Hidekazu Todoroki | |||
| Kazuhisa Katayama | |||
| Kazuo Shimada | |||
| Megumi Teraoka | |||
| Toshihiro Koga | |||
| Yasuhiro Okumura | |||
| P2860 | cites work | Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 |
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer | Q28728701 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme | Q33561588 | ||
| PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib | Q33933626 | ||
| Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells | Q34156192 | ||
| Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens | Q34342079 | ||
| Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers | Q34679149 | ||
| Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial | Q35584284 | ||
| Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation | Q35889621 | ||
| Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. | Q36021424 | ||
| Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer | Q36064908 | ||
| HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer | Q37136419 | ||
| Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status | Q37221249 | ||
| Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment | Q37507467 | ||
| Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001) | Q37641066 | ||
| P95 HER2 fragments and breast cancer outcome | Q38223511 | ||
| Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients | Q39674995 | ||
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | Q40144433 | ||
| Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects | Q45141053 | ||
| Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff | Q46058629 | ||
| Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer | Q46610979 | ||
| p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer | Q46905262 | ||
| PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. | Q52874022 | ||
| Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. | Q53394493 | ||
| Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. | Q54660064 | ||
| P433 | issue | 1 | |
| P921 | main subject | capecitabine | Q420207 |
| biomarker | Q864574 | ||
| P304 | page(s) | 51-61 | |
| P577 | publication date | 2017-05-06 | |
| P1433 | published in | Oncology | Q2016300 |
| P1476 | title | Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. | |
| P478 | volume | 93 |
| Q100751537 | Attenuation of p53 mutant as an approach for treatment Her2-positive cancer |
| Q58112887 | Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer |
| Q59798481 | Human epithelial growth factor receptor 2 in human salivary carcinoma ex pleomorphic adenoma: a potential therapeutic target |
| Q90729183 | Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population |
| Q90316294 | MiR-519d targets HER3 and can be used as a potential serum biomarker for non-small cell lung cancer |
| Q47136119 | Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab |
| Q90862850 | Targeted therapeutic options and future perspectives for HER2-positive breast cancer |
Search more.